Method of measurement for tazobactam/piperacillin concentration in body fluid by bioassay and high-performance liquid chromatography

• Published in: CHEMOTHERAPY Vol. 42; no. Supplement2; pp. 263 - 276
• Main Authors: Sakawa, Kumiko, Sasaki, Toru, Otani, Toshio, Hyodo, Akio, Ishida, Naobumi, Nishikawa, Masako, Umeno, Yukihiko
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1994
• Subjects: Bioassay; Biological fluid; HPLC; TAZ/PIPC; tazobactam/piperacillin
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.42.Supplement2_263

We established a microbiological assay method and high-performance liquid chromatography (HPLC) method for the quantitative determination of tazobactam/piperacillin (TAZ/PIPC=1:4) in body fluid. In the bioassay method, the TAZ concentration was determined by using Escherichia coli 603 as a test organism in Mueller-Hinton medium (Difco) containing 150 μg/ml of cefoperazone. The PIPC concentration was determined by using Micrococcus luteus ATCC 9341 as a test organism. In the HPLC method, the concentrations of TAZ, PIPC and desethyl-PIPC, which is an active metabolite in humans, were determined simultaneously on an Inertsil ODS-2 column using a linear gradient elution with acetonitrile and 10 mM phosphate buffer solution (pH 5.5). The concentration of M-1, which is an inactive metabolite of TAZ, was determined using a Develosil ODS-5 column. The concentrations of TAZ and PIPC determined by the bioassay method correlated well with those measured by the HPLC method.